Lateral Epicondylitis (Tennis Elbow) Disease - Market Insight, Epidemiology and Market Forecast - 2034

Key Highlights

• More than half of non-professional tennis players experience lateral epicondylitis, while only about 5% of professional players report the condition. Nonetheless, many other sports and activities can also increase the risk of lateral epicondylitis.
• Tennis elbow is one of the most common causes of elbow pain. Even though it’s named for tennis, that’s not the most common cause. Experts estimate that more than 9 in 10 people develop it for other reasons.
• Approximately 80 to 95% of patients have success with non-surgical treatment.
• First-line management for the treatment of lateral epicondylitis includes rest from offending activity as guided by the level of pain. Specific exercises help strengthen the muscles of the forearm.
• Acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen or naproxen, may be taken to help reduce pain and swelling.
• Platelet-rich plasma (PRP) is a biological therapy aimed at enhancing the tissue’s healing environment, while corticosteroids, such as cortisone, are commonly used to reduce inflammation and pain.
• Surgery should be considered as a last resort in the management of lateral epicondylitis. Prolonged non-operative management (i.e., 6-12 months) should be attempted before considering surgical management.
• Currently, there are no approved therapies for lateral epicondylitis, and the mainstay of treatment relies on the off-label use of NSAIDs along with structured physical exercise.
• The emerging pipeline for lateral epicondylitis remains limited, with Causeway Therapeutics’ TenoMiR (CWT-001) currently in Phase II clinical trials.

The “Lateral Epicondylitis - Market Insight, Epidemiology and Market Forecast - 2034” report delivers an in-depth analysis of lateral epicondylitis epidemiology, market, and clinical development in lateral epicondylitis. In addition to this, the report provides historical and forecasted epidemiology and market data as well as a detailed analysis of the lateral epicondylitis market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

The lateral epicondylitis market report provides real-world prescription pattern analysis, emerging drugs assessment, market share, and uptake/adoption pattern of individual therapies, as well as historical and forecasted lateral epicondylitis market size from 2020 to 2034 in 7MM. The report also covers current lateral epicondylitis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Lateral Epicondylitis Understanding and Treatment Algorithm

Lateral Epicondylitis Overview

Lateral epicondylitis, also commonly referred to as tennis elbow, describes an overuse injury secondary to an eccentric overload of the common extensor tendon at the origin of the Extensor Carpi Radialis Brevis (ECRB) tendon. Tennis elbow primarily results from the repetitive strain caused by activities that involve loaded and repeated gripping and/or wrist extension. It is common in individuals who play tennis, squash, badminton, or any activity involving repetitive wrist extension, radial deviation, and/or forearm supination.

Lateral Epicondylitis Diagnosis

Lateral epicondylitis is a clinical diagnosis, and imaging is often not necessary. A provider may consider obtaining an elbow radiographic series (anteroposterior and lateral) if other injuries or conditions are suspected by history and/or physical exam. Other conditions warranting potential imaging workup include evaluating concomitant degenerative joint changes, fractures, tumors, or bursitis. If the patient is not responding to non-operative management modalities, the provider may consider ordering an MRI or ultrasound to evaluate for tears, stress fractures, or osteochondral defects.

Lateral Epicondylitis Treatment

First-line management of lateral epicondylitis involves rest from aggravating activities based on pain levels, along with the use of ice after activity and oral or topical NSAIDs for pain relief. Forearm counterforce straps may help reduce tension on the lateral epicondyle during activity, though their effectiveness is debated due to potential discomfort from pressure on the tender area. A wrist cock-up splint can also be used to reduce strain on the wrist extensors. Physical or occupational therapy focusing on forearm stretching and strengthening - particularly eccentric strengthening of the common extensor tendon - has shown positive results. If symptoms persist despite conservative measures, more advanced options such as topical nitrates, botulinum toxin injections, platelet-rich plasma (PRP), or dextrose prolotherapy may be considered. Surgical intervention is reserved for chronic, refractory cases after 6 to 12 months of failed non-operative treatment and typically involves debridement or release of the extensor carpi radialis brevis (ECRB) origin at the lateral epicondyle to remove pathologic tissue and stimulate healing.

Currently, there are no approved therapies for lateral epicondylitis, and the mainstay of treatment relies on the off-label use of NSAIDs along with structured physical exercise.

Lateral Epicondylitis Epidemiology

The lateral epicondylitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total prevalent cases of lateral epicondylitis, age-specific prevalent cases of lateral epicondylitis, gender-specific prevalent cases of lateral epicondylitis, and type-specific prevalent cases of lateral epicondylitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• Lateral epicondylitis is estimated to affect 1-3% of the adult population each year and is more common in the dominant arm.
• Lateral epicondylitis affects both males and females, but studies suggest it is slightly more common in females and is more common in individuals aged 30-60, particularly those in the 45-54 age range.
• Lateral epicondylitis affects about 4 to 7 out of every 1,000 people. Although it's often called "tennis elbow," tennis player’s account for only 10% of those diagnosed.

Lateral Epicondylitis Drug Chapters

The drug chapter segment of the lateral epicondylitis report encloses a detailed analysis of lateral epicondylitis mid and early stage (Phase II) pipeline drugs. It also deep dives into lateral epicondylitis’s pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Emerging Drugs

TenoMiR (CWT-001): Causeway Therapeutics

TenoMiR is a novel microRNA-based therapeutic candidate intended to enhance tendon healing by improving collagen quality in patients with tennis elbow, potentially offering a more effective and timely treatment option compared to current therapies.

TenoMiR is a one-time injectable therapy for the treatment of lateral epicondylitis, administered directly into the damaged tendon under ultrasound guidance to ensure precise delivery to the site of injury. TenoMiR is currently in a multi-site Phase II clinical trial in patients with lateral epicondylitis in both the US and the UK.

Drug Class Insights

MicroRNA-29a (miR-29a)

MicroRNA-29a can help treat tennis elbow by restoring balance in tendon collagen production. In tendon injuries, reduced miR-29a leads to excess collagen type III, which weakens tendon structure. Supplementing miR-29a, such as through therapies like TenoMiR, lowers collagen III without affecting collagen I, improving tendon quality, reducing degeneration, and enhancing healing. This targeted molecular approach promotes stronger tendon repair and may speed recovery in lateral epicondylitis.

Lateral Epicondylitis Market Outlook

Currently, there are no approved therapies for lateral epicondylitis. Conservative treatment of lateral epicondylitis includes NSAIDs, analgesics, topical corticosteroid application, rest, cryotherapy, acupuncture, kinesitherapy, physical therapy including ultrasound, iontophoresis, deep transverse frictions, shock wave and laser therapy, manual therapy, and exercises strengthening the muscles. Wearing an epicondylar bandage is also a part of conservative treatment. There are insufficient data on the efficacy of NSAIDs on pain compared with injectable corticosteroids, but as a global effect on symptoms, NSAIDs have shown lower efficacy.

Different combinations of exercises have also been used for the treatment. They are usually part of a complex treatment. Despite controversial results, there is evidence from several randomized controlled trials that exercise may be more effective in reducing pain and improving arm function than other procedures, such as ultrasound, placebo ultrasound, and manual therapy, but there is no difference in muscle strength and function between various types of exercises. Manual therapy for the elbow, wrist, and cervicothoracic spine can reduce pain and increase the strength of the pain-free grip immediately after treatment. Unfortunately, meta-analysis is not possible due to heterogeneity between manual therapy techniques and follow-up time. There is insufficient evidence of the long-term clinical effects of manual therapy alone in lateral epicondylitis.

The use of laser therapy in lateral epicondylitis is effective in the short term compared to placebo, but in the long term, however, no advantages are found compared to other physical methods. Lasers with a wavelength other than 904 nm did not show better efficacy than placebo.

The development pipeline for lateral epicondylitis remains sparse, with TenoMiR (CWT-001) by Causeway Therapeutics being the only notable candidate currently in Phase II clinical trials. This significant unmet clinical need presents a strong opportunity for industry stakeholders to advance research and development efforts aimed at addressing this therapeutic void.

Lateral Epicondylitis Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025-2034, which depends on the competitive landscape, safety, and efficacy data, along with the order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Lateral Epicondylitis Pipeline Development Activities

The report provides insights into different therapeutic candidates in the Phase II stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for lateral epicondylitis therapies.

KOL Views

To keep up with the real-world scenario in current and emerging market trends, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including the MD, the Director, a Researcher, Medical/Scientific Writers, Professors, and Others.

The analysts connected with 15+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the University of Colorado Health Sciences Center, UT Southwestern Medical Center in Dallas, Barts Centre in London, LUNGevity Foundation, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or lateral epicondylitis market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT Analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated.

Further, the therapies’ safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of lateral epicondylitis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging therapies, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the lateral epicondylitis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM lateral epicondylitis market.

Lateral Epicondylitis Report Insights

• Patient Population
• Therapeutic Approaches
• Lateral Epicondylitis Pipeline Analysis
• Lateral Epicondylitis Market Size and Trends
• Existing and future Market Opportunity

Lateral Epicondylitis Report Key Strengths

• Ten-Years Forecast
• 7MM Coverage
• Lateral Epicondylitis Epidemiology Segmentation
• Key Cross Competition
• Conjoint analysis
• Drugs Uptake and Key Market Forecast Assumptions

Lateral Epicondylitis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What is the historical and forecasted lateral epicondylitis patient pool/patient burden in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan?
• Which combination of treatment approaches will have a significant impact on the lateral epicondylitis drug treatment market size?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
• What are the current and emerging options for the treatment of lateral epicondylitis?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies?
• How many key players are developing therapies for lateral epicondylitis?
• Which drug is the major contributor to the lateral epicondylitis market by 2034?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the lateral epicondylitis market.
• Insights on patient burden/disease Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of access and reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.